SCH 497079

SCH 497079 is an investigational small molecule drug developed by Schering-Plough (now Merck) as an orally active antagonist of the histamine H3 receptor. Its primary mechanism of action is to block the histamine H3 receptor, which plays a role in regulating neurotransmitter release and appetite control. The drug was primarily investigated for the treatment of obesity, with additional exploration in metabolic disorders such as type 2 diabetes and weight gain. Clinical trials included phase 1 and phase 2 studies evaluating its efficacy on weight loss, metabolic parameters, and nasal congestion (in combination with desloratadine). Development was discontinued after phase 2 trials for obesity[1][2][3][4][5].